Innovative traditional Chinese medicines ushered in the harvest period, and 4 products were approved for marketing in November

 In recent years, with the successive promulgation of national support policies for Chinese medicine, the Chinese medicine industry has entered a period of vigorous development, and Chinese medicine companies have ushered in rare development opportunities
.
In this context, more and more Chinese medicine companies have begun to seize development opportunities to strengthen the research and development of Chinese medicine products
.
The author was informed that since November, the field of innovative Chinese medicines has also ushered in a harvest period, and a total of 4 innovative Chinese medicines have been approved for marketing
.
According to the news on the website of the State Drug Administration on November 26, the State Drug Administration has recently approved three innovative Chinese medicines: Xuanqijian Bone Tablets, Qizhi Yishen Capsules, and Kunxinning Granules
.
In addition to the approval of the above three innovative Chinese medicines, the National Medical Products Administration also approved the registration application for Yinqiao Qingre Tablets in November, which means that a total of 4 innovative Chinese medicines have been approved for marketing
.
Xuanqijian bone tablets of Fangsheng Pharmaceutical According to the results of clinical trials, Xuanqijian bone tablets can be used for the treatment of mild to moderate knee osteoarthritis in TCM syndromes
.
Marketing authorization holder is Fang Sheng Pharmaceutical Co.
, Ltd.
, Hunan
.
It is understood that Fangsheng Pharmaceutical takes "new drug research and development capabilities" as its core competitive advantage and has established a strategy of "Chinese medicine, chemical medicine, and biological medicine" simultaneously
.
Among them, in the field of traditional Chinese medicine, Fangsheng Pharmaceutical has successfully developed several series of products such as "Xinxuean" cardiovascular and cerebrovascular department, "Jin Beibei" brand pediatrics, and "Fang Shengtang" brand orthopedics
.
Qizhi Yishen Capsules of Phoenix Pharmaceuticals According to the results of clinical trials, Qizhi Yishen Capsules can be used to treat early diabetic nephropathy with deficiency of both Qi and Yin
.
Its marketing authorization holder for Phoenix Pharmaceutical Co.
, Ltd.
, Shandong
.
It is understood that at the beginning of its establishment, Phoenix Pharmaceuticals established the construction policy of "emphasizing traditional Chinese medicine, combining synthetic drugs, and developing biological drugs"
.
Innovation is the fundamental driving force for enterprise development.
In recent years, Phoenix Pharmaceuticals has continuously increased R&D investment and is committed to technological breakthroughs.

.
In the development of traditional Chinese medicine, Phoenix Pharmaceuticals has developed innovative drugs such as Tiandan Tongluo Capsules, Fufang Chuanxiong Capsules, Jinshi Qingre Granules, and Nuzhen Granules with independent intellectual property rights
.
The Chinese medicine project under development includes Qihuang Capsules
.
Kun Ning heart Tasly particles Kun Xin Ning particles are 1.
1 class of innovative medicine, formerly known as Kun Yi-ning particles, indicated for menopausal syndrome, marketing authorization holder is Tasly Pharmaceutical Group Co.
, Ltd
.
Tasly said that the approval of Kunxinning granules is the third important progress Tasly has made in the field of traditional Chinese medicine research and development in recent months.
It shows that the company has begun to ripen after long-term investment and enter the harvest period
.
It is understood that Tasly, a modern Chinese medicine company in China, continues to increase R&D investment.
Data shows that in 2020, Tasly’s R&D investment will reach 600 million yuan, with 1295 R&D personnel, accounting for 13.
95% of the company’s total employees
.
In addition, according to Tasly's semi-annual report, Tasly has leveraged the synergistic development advantages of modern innovative Chinese medicine, chemical medicine, and biological medicine to continuously enrich the company's full life cycle product portfolio based on the pathophysiological evolution of diseases
.
At present, Tasly has deployed 28 products in the field of modern Chinese medicine, further consolidating the company's leading position in the research and development of Chinese medicine
.
Kangyuan Pharmaceutical's Class 1.
1 New Drug Yinqiao Qingre Tablets On November 15, Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, and approved the company's 1.
1 category new drug Yinqiao Qingre The tablet is on the market for the treatment of exogenous wind-heat type common cold
.
The launch of Kangyuan Pharmaceutical Yinqiao Qingre Tablets will provide a new treatment option for patients with exogenous wind-heat common cold.
Kangyuan Pharmaceutical will also adopt intelligent pharmaceuticals with independent intellectual property rights in the process of industrialization.
Technology implements refined manufacturing, continuously improves product quality, and makes continuous efforts to provide patients with safer, more effective and high-quality drugs
.
It is understood that in recent years, we have continued to promote the reform of the Chinese medicine review and approval mechanism, established and improved the registration management system and technical evaluation system in line with the characteristics of Chinese medicine, and accelerated the development of new Chinese medicines based on clinical value, and continuously achieved new breakthroughs in the field of innovative Chinese medicines.

.
According to statistics, as of 2021, a total of 9 new Chinese medicines have been approved for marketing, and the reform of the Chinese medicine review and approval system has begun to show results
.
In addition, some data predict that by 2024, China's proprietary Chinese medicine market is expected to reach 1,137.
5 billion yuan
.